BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 33262254)

  • 1. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
    Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
    Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
    Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.
    Qin Y; Petaccia de Macedo M; Reuben A; Forget MA; Haymaker C; Bernatchez C; Spencer CN; Gopalakrishnan V; Reddy S; Cooper ZA; Fulbright OJ; Ramachandran R; Wahl A; Flores E; Thorsen ST; Tavera RJ; Conrad C; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Amaria RN; Hwu P; Wargo JA; Lazar AJ; Patel SP
    Oncoimmunology; 2017; 6(6):e1321187. PubMed ID: 28680759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immune cell landscape of metastatic uveal melanoma correlates with overall survival.
    Tosi A; Cappellesso R; Dei Tos AP; Rossi V; Aliberti C; Pigozzo J; Fabozzi A; Sbaraglia M; Blandamura S; Del Bianco P; Chiarion-Sileni V; Rosato A
    J Exp Clin Cancer Res; 2021 May; 40(1):154. PubMed ID: 33947438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
    Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.
    Johnson DB; Bao R; Ancell KK; Daniels AB; Wallace D; Sosman JA; Luke JJ
    J Natl Compr Canc Netw; 2019 Feb; 17(2):114-117. PubMed ID: 30787124
    [No Abstract]   [Full Text] [Related]  

  • 10. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value.
    Barnhill R; van Dam PJ; Vermeulen P; Champenois G; Nicolas A; Rawson RV; Wilmott JS; Thompson JF; Long GV; Cassoux N; Roman-Roman S; Busam KJ; Scolyer RA; Lazar AJ; Lugassy C
    J Pathol Clin Res; 2020 Jul; 6(3):195-206. PubMed ID: 32304183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma.
    Stålhammar G; Seregard S; Grossniklaus HE
    Cancer Med; 2019 Jun; 8(6):2784-2792. PubMed ID: 30993893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma.
    Bustamante P; Miyamoto D; Goyeneche A; de Alba Graue PG; Jin E; Tsering T; Dias AB; Burnier MN; Burnier JV
    Cancer Med; 2019 Dec; 8(17):7265-7277. PubMed ID: 31588689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.
    Rothermel LD; Sabesan AC; Stephens DJ; Chandran SS; Paria BC; Srivastava AK; Somerville R; Wunderlich JR; Lee CC; Xi L; Pham TH; Raffeld M; Jailwala P; Kasoji M; Kammula US
    Clin Cancer Res; 2016 May; 22(9):2237-49. PubMed ID: 26712692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
    Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
    Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
    Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
    García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
    Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
    JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
    Jindal V
    Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
    Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
    Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres.
    de Leede EM; Burgmans MC; Kapiteijn E; Luyten GP; Jager MJ; Tijl FG; Hartgrink HH; Grünhagen DJ; Rothbarth J; van de Velde CJ; Verhoef C; Vahrmeijer AL
    Melanoma Res; 2016 Dec; 26(6):588-594. PubMed ID: 27513071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.